Precigen's third quarter of 2025 demonstrated a strong commercial launch of its breakthrough treatment Papcemias, which received FDA approval in August, paving the way for it to become the standard of care for recurrent respiratory papillomatosis (RRP).

• Papcemias achieved FDA approval with a broad label, marking it as the first and only treatment for adults with RRP.
• The pivotal clinical trial results showed 51% of patients achieved a complete response with no surgery required for 12 months, and 86% experienced reduced surgical burden.
• Precigen's sales team has engaged 90% of target institutions, resulting in multiple national formulary approvals and over 100 patients registered in the Precigen patient services hub.
• Strong payer coverage is already in place, with over 80 million lives covered, facilitating rapid market access.